Clinical trials: Prostate Cancer Recurrent
Biochemical Relapse Fo Malignant Neoplasm of Prostate
18F-FACBC PET/CT and the PSA Kinetics for PCa Patients With Biochemical Recurrence.
Prostate cancer (PCa) is the fifth-most common cancer for male with a seventh highest cancer-related death in Taiwan. Currently, the incidence and mortality rate are still increasing rapidly.
- Trial name
- NCT05048537
- Testing
- 18F-FACBC PET/CT
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence…
- Trial name
- NCT04186845
- Testing
- rhPSMA-7.3 (18F) Injection, Positron emission tomography scan
- Where
- 28 sites in United States, Finland and 1 more
- Volunteers
- 391 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer, Recurrent Prostate Cancer
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Background: Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed.
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, PET Positive
- Trial name
- NCT06096870
- Testing
- Enzalutamide, PDS01ADC
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00459810
- Testing
- transdermal estradiol, paclitaxel poliglumex
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device
The aim of this registry is to assess the recurrence of prostate cancer at 1 and 5 years, as well as the change in functional outcomes (e.g. incontinence or erectile function) from baseline.
- Trial name
- NCT02255890
- Where
- Netherlands
- Volunteers
- 361 people
- Sponsor
- Clinical Research Office of the Endourological Society
Prostate Cancer Recurrent
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Treatment of recurrent oligometastatic prostate cancer may be enhanced by the addition of Hydroxychloroquine to the current treatment regimens.
- Trial name
- NCT04011410
- Testing
- Hydroxychloroquine Sulfate 200Mg Tab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Patrick Hensley
Prostate Cancer
Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer
RATIONALE: Soy protein may help prevent prostate cancer recurrence in patients who have undergone surgery for prostate cancer. PURPOSE: This randomized phase II/III trial is studying how well soy protein works and compares it to…
- Trial name
- NCT00765479
- Testing
- soy protein isolate
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- University of Illinois at Chicago
Prostate Cancer
Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer
Radiation therapy is considered a standard treatment option for the management of localized prostate cancer. Among the 20-30% who recur, a proportion of them will present with an isolated local recurrence, meaning no distant…
- Trial name
- NCT01583920
- Testing
- focal salvage HDR prostate brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with…
- Trial name
- OSPREY (NCT02981368)
- Testing
- 18F-DCFPyL Injection, PET/CT imaging
- Where
- 10 sites in United States, Canada
- Volunteers
- 385 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Metastatic Cancer, Prostate Cancer
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554918
- Testing
- docetaxel, prednisolone, zoledronic acid
- Where
- 16 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University Hospital Birmingham
Breast Cancer, Kidney Cancer
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
RATIONALE: Genistein may increase the effectiveness of radiation therapy in treating pain caused by bone metastases. PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma
- Trial name
- NCT00769990
- Testing
- genistein, radiation therapy
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Cancer
Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer
RATIONALE: Ultrasound therapy kills tumor cells by heating them to several degrees above body temperature. This treatment may be effective for prostate cancer.
- Trial name
- NCT00005075
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States
- Sponsor
- EDAP Technomed
Prostate Carcinoma
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion…
- Trial name
- ECLIPSE (NCT07185165)
- Testing
- Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, Esophageal Cancer
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT01172028
- Testing
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Arizona
Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer
Cabozantinib in Men With Castration-Resistant Prostate Cancer
This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01703065
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Prostate Cancer
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
This is a prospective, multicentre, open-labelled, randomized controlled trial comparing the efficacy of immediate versus deferred androgen deprivation therapy (ADT) using goserelin (Zoladex®) in men with recurrent prostate…
- Trial name
- ELAAT (NCT00439751)
- Testing
- Goserelin Acetate
- Where
- 11 sites in Canada
- Volunteers
- 79 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional…
- Trial name
- NCT05169112
- Testing
- Lupron Depot
- Where
- 3 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
Docetaxel in Treating Patients With Relapsed Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482274
- Testing
- docetaxel
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
This phase II trial evaluates Fluorine-18 radiohybrid prostate-specific membrane antigen (18F- rhPSMA)-7.3 positron emission tomography (PET)/computed tomography (CT) scans with and without furosemide for the reduction of bladder…
- Trial name
- NCT05779943
- Testing
- Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University